Literature DB >> 6101522

Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics.

G Chouinard, B D Jones.   

Abstract

Tardive dyskinesia is thought to result from neostriatal dopaminergic receptor supersensitivity induced by chronic treatment with neuroleptics. The authors suggest that dopaminergic supersensitivity also occurs in the mesolimbic region after chronic neuroleptic exposure, resulting in the development of a supersensitivity psychosis. Neuroleptic-induced supersensitivity psychosis is illustrated by data from 10 patients that demonstrate the syndrome's clinical and pharmacologic characteristics. An implication of neuroleptic-induced mesolimbic supersensitivity is that the tenaency toward psychotic relapse in such patients is determined by more than just the normal course of the illness.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6101522     DOI: 10.1176/ajp.137.1.16

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  46 in total

Review 1.  Antipsychotic dosing: how much but also how often?

Authors:  Gary Remington; Shitij Kapur
Journal:  Schizophr Bull       Date:  2010-07-21       Impact factor: 9.306

2.  Successful management of clozapine adverse effects with extended (alternate day) antipsychotic dosing in a patient with schizophrenia.

Authors:  Vijaya Kumar; Lavanya Sharma; Srikanth Madival; Ganesan Venkatasubramanian
Journal:  J Psychiatry Neurosci       Date:  2016-01       Impact factor: 6.186

Review 3.  Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations.

Authors:  Anja Cerovecki; Richard Musil; Ansgar Klimke; Florian Seemüller; Ekkehard Haen; Rebecca Schennach; Kai-Uwe Kühn; Hans-Peter Volz; Michael Riedel
Journal:  CNS Drugs       Date:  2013-07       Impact factor: 5.749

4.  What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?

Authors:  Christoph U Correll; Jose M Rubio; John M Kane
Journal:  World Psychiatry       Date:  2018-06       Impact factor: 49.548

5.  Clozapine response trajectories and predictors of non-response in treatment-resistant schizophrenia: a chart review study.

Authors:  Parita Shah; Yusuke Iwata; Eric E Brown; Julia Kim; Marcos Sanches; Hiroyoshi Takeuchi; Shinichiro Nakajima; Margaret Hahn; Gary Remington; Philip Gerretsen; Ariel Graff-Guerrero
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-08-19       Impact factor: 5.270

6.  Effect of extended depot fluphenazine treatment and withdrawal on social and other behaviors of Cebus apella monkeys.

Authors:  K Lifshitz; R T O'Keeffe; K L Lee; G S Linn; D Mase; J Avery; E S Lo; T B Cooper
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

Review 7.  Pharmacologic features and effects of neuroleptics.

Authors:  M V Seeman
Journal:  Can Med Assoc J       Date:  1981-10-15       Impact factor: 8.262

8.  Behavioral adaptation in C. elegans produced by antipsychotic drugs requires serotonin and is associated with calcium signaling and calcineurin inhibition.

Authors:  Dallas R Donohoe; Raymond A Jarvis; Kathrine Weeks; Eric J Aamodt; Donard S Dwyer
Journal:  Neurosci Res       Date:  2009-04-05       Impact factor: 3.304

9.  Supersensitivity psychosis in schizophrenic patients after sudden clozapine withdrawal.

Authors:  B Ekblom; K Eriksson; L H Lindström
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

Review 10.  A meta-analysis of the response to chronic L-dopa in patients with schizophrenia: therapeutic and heuristic implications.

Authors:  George E Jaskiw; Anand P Popli
Journal:  Psychopharmacology (Berl)       Date:  2003-12-11       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.